GENERAL
Biocon Launches Interchangeable Eye Drug Biosimilar Yesafili In US Market
Biocon Ltd has commercially launched Yesafili, its interchangeable biosimilar to blockbuster eye drug Eylea (aflibercept) 2 mg, in the United States, marking a significant expansion of its ophthalmology portfolio in the world’s largest pharmaceutical market. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of various retinal disorders, including age-related macular […]
CW Bureau
·
Aug 3, 2026
GENERAL
Glenmark Scales Up US Injectables Presence With Generic Sugammadex
Glenmark Pharmaceuticals Inc., USA, has launched Sugammadex Injection in the United States, expanding its injectables portfolio with a generic version of Merck Sharp & Dohme LLC’s blockbuster anaesthesia reversal drug BRIDION. The company said the product is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. Glenmark’s Sugammadex Injection […]
CW Bureau
·
Jul 29, 2026
GENERAL
Cipla Gets US FDA Nod For Generic Advair Diskus; Scales COPD Portfolio
Drugmaker Cipla Ltd has received approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for the generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three dosage strengths. The approval covers 100/50 mcg, 250/50 mcg and 500/50 mcg strengths. The product is therapeutically […]
CW Bureau
·
Jul 28, 2026
